Claramine trifluoroacetate salt
SIGMA/SML1545 - ≥98% (HPLC)
Synonym: (3β,6β)-6-[[3-[[4-[(3-Aminopropyl)amino]butyl]amino]propyl]amino]-cholestan-3-ol trifluoroacetate salt
Empirical Formula (Hill Notation): C37H72N4O · xC2HF3O2
Molecular Weight: 588.99 (free base basis)
Linear Formula: C37H72N4O · xC2HF3O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| Quality Level | 100  |
| solubility | H2O: 15 mg/mL, clear |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Claramine is a more conveniently-manufactured lead compound for the derivation of therapeutic agents. It is believed to be useful for the treatment of type II diabetes. Claramine is capable of crossing blood brain barrier (BBB) and is thought to mediate its action through hypothalamus, which is responsible for maintaining metabolic homeostasis. Claramine A1 is found effective against multidrug resistant bacteria and nosocomial diseases. |
| Biochem/physiol Actions: | Claramine is a protein tyrosine phosphatase 1B (PTP1B) inhibitor, an analog of Trodusquemine. Like Trodusquemine, Claramine is a selective inhibitor of protein tyrosine phosphatase 1B (PTB1B), and not its closest related phosphatase TC-PTP. Claramine activated insulin signaling, increasing phosphorylation of insulin receptor-β (IRβ), Akt and GSK3β. It improved insulin sensitivity, restoring glycemic control in diabetic mice, and caused weight loss by suppressing food intake. |
| General description: | Claramine is an easy and quick to synthesize polyaminosteroid derivative. It is a trodusquemine-related compound and shares with it a spermino group, which is responsible for its inhibitory action towards protein tyrosine phosphatase 1B (PTP1B). |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352116 |